Holen Sie sich die Stockscreener-App
3.195
3.67%
0.145
Prokidney Corp Aktie (PROK) Neueste Nachrichten
ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement - MSN
Meet the Biotech Stock That Rocketed 775% Higher - AOL.com
What analysts say about ProKidney Corp. stockExplosive capital gains - Autocar Professional
What drives ProKidney Corp. stock priceSky-high profits - Autocar Professional
Is ProKidney Corp. a good long term investmentExtraordinary market timing - jammulinksnews.com
11 Best High Return Penny Stocks to Buy Now - Insider Monkey
ProKidney Corp. Stock Analysis and ForecastDynamic profit expansion - Autocar Professional
JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK) - MSN
ProKidney Corp. (PROK): Navigating Clinical Pivotality and Market Volatility in the Race for a CKD Breakthrough - AInvest
JP Morgan Maintains Neutral Stance on ProKidney Corp., Citing Extended Timeline for Key Data - AInvest
New Strong Buy Stocks for July 17th - MSN
10 Hot Penny Stocks to Invest in Now - Insider Monkey
ProKidney Shares Dip Following FDA Agreement on Rilparencel Approval Strategy - MSN
PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy? - Mitrade
Best Momentum Stocks to Buy for July 17th - Nasdaq
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - MSN
ProKidney gains pivotal therapy advancement step with FDA - Winston-Salem Journal
ProKidney completes Delaware domestication and restructures corporate agreements By Investing.com - Investing.com Nigeria
ProKidney completes Delaware domestication and restructures corporate agreements - Investing.com
Citi Maintains ProKidney(PROK.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Will ProKidney’s Recent Surge Last? - StocksToTrade
ProKidney’s Clinical Trials and Regulatory Developments Lead to Hold Rating Amid Uncertainty - TipRanks
ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
ProKidney’s Hold Rating: Balancing FDA Alignment and Extended Approval Timeline - TipRanks
ProKidney’s Strategic FDA Alignment and Promising Clinical Data Drive Buy Rating - TipRanks
ProKidney price target raised to $7 from $6 at Guggenheim - MSN
ProKidney’s Dramatic Shares Tumble - timothysykes.com
Is ProKidney’s Slide a Buy Signal? - StocksToTrade
ProKidney Shares Plummet Amid Downgrades - timothysykes.com
UBS Initiates ProKidney(PROK.US) With Buy Rating, Announces Target Price $8 - 富途牛牛
ProKidney Shares Surge in Early Trading On FDA Support for Kidney Drug Trial - MarketScreener
ProKidney Stock Skyrockets: What Does This Mean? - StocksToTrade
ProKidney, FDA align on accelerated approval pathway for Rilparencel - MSN
UBS Adjusts ProKidney Price Target to $8 From $4, Maintains Buy Rating - MarketScreener
ProKidney stock soars after FDA confirms accelerated approval pathway - Investing.com
Sector Update: Health Care - MarketScreener
ProKidney Soars 29.27% on FDA Milestone for CKD Therapy - AInvest
ProKidney Says FDA Confirms Accelerated Approval Pathway for Rilparencel - MarketScreener
Prokidney announces alignment with the FDA on the accelerated approval pathway for rilparencel - MarketScreener
ProKidney stock falls after FDA alignment on rilparencel approval pathway - Investing.com
ProKidney announces alignment with the FDA on the accelerated approval pathway for rilparencel - grafa.com
4.74%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):